The Surge in the Number of Circulating Tumor Cells Following Treatment with Sunitinib for Metastatic Renal Cell Carcinoma

Nagaya, Naoya; Kanayama, Mayuko; Nagata, Masayoshi; Horie, Shigeo

doi:10.2169/internalmedicine.0663-17

Cited by 6 publications

(7 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They concluded that the recurrence or metastasis of RCC was probably related to the variation trend of CTCs. Recently, Nagaya et al described a metastatic RCC patient, whose CTC counts rapidly increased after sunitinib treatment and then gradually decreased [ 39 ]. This result suggested that CTCs, as a promising biomarker, may be helpful for promptly monitoring the treatment response.…”

Section: Discussionmentioning

confidence: 99%

Clinical significance of circulating tumour cells and Ki-67 in renal cell carcinoma

Song

Dong

et al. 2021

World J Surg Onc

View full text Add to dashboard Cite

Background Renal cell carcinoma (RCC) is a common malignant tumour of the genitourinary system. We aimed to analyse the potential value of metastasis-related biomarkers, circulating tumour cells (CTCs) and the proliferative marker Ki-67 in the diagnosis of RCC. Methods Data from 24 laparoscopic radical nephrectomies (RNs) and 17 laparoscopic partial nephrectomies (PNs) were collected in 2018. The numbers and positive rates of CTCs and circulating tumour microemboli (CTM) in the peripheral blood were obtained at three different time points: just before surgery, immediately after surgery and 1 week after surgery. Ki-67 protein expression was evaluated in the RCC tissue by immunohistochemistry. Results Except for the statistically significant association between the preoperative CTC counts and tumour size, no association between the number and positive rate of perioperative CTCs and clinicopathological features was found. The CTC counts gradually decreased during the perioperative period, and at 1 week after surgery, they were significantly lower than those before surgery. High Ki-67 expression was significantly positively correlated with preoperative CTC counts. In addition, Ki-67 expression was higher in the high CTC group (≥ 5 CTCs). Conclusion Our results suggest that surgical nephrectomy is associated with a decrease in CTC counts in RCC patients. CTCs can act as a potential biomarker for the diagnosis and prognosis of RCC. A careful and sufficient long-term follow-up is needed for patients with high preoperative CTC counts.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical significance of circulating tumour cells and Ki-67 in renal cell carcinoma

Song

Dong

et al. 2021

World J Surg Onc

View full text Add to dashboard Cite

show abstract

“…Surprisingly, a recent case report describing the use of an EpCAM-based microfluidic isolation of circulating epithelial cells by CytoQuest CR (Abnova, Taipei, Taiwan) and cytokeratin positivity, as a marker for CTC detection, managed to correlate CTC kinetics with response to sunitinib treatment of a metastatic RCC patient over a period of 20 days [ 25 ]. Although, said correlation emerged solely from the observation that, while CTC numbers dropped below baseline count at Day 20, CTscan examination on Day 128 showed a 14% reduction in the size of the primary renal lesion with concomitant shrinkage of the lung metastasis.…”

Section: Ctc Collection/detection In Renal Cell Carcinomamentioning

confidence: 99%

“…Indeed, circulating epithelial cell numbers have been shown to correlate with inflammation status in benign colon diseases [ 54 ] while circulating endothelial cells, which can also express cytokeratins, are known to correlate with pulmonary hypertension [ 60 ]. Therefore, the study by Nagaya et al raises further issues concerning the specificity of cytokeratin-based CTC counting, especially since their case report did not include any healthy controls [ 25 ].…”

Section: Ctc Collection/detection In Renal Cell Carcinomamentioning

confidence: 99%

Circulating Tumor Cells for the Management of Renal Cell Carcinoma

Broncy

Paterlini‐Bréchot

2018

Diagnostics

View full text Add to dashboard Cite

Renal cell carcinoma is a highly malignant cancer that would benefit from non-invasive innovative markers providing early diagnosis and recurrence detection. Circulating tumor cells are a particularly promising marker of tumor invasion that could be used to improve the management of patients with RCC. However, the extensive genetic and immunophenotypic heterogeneity of cells from RCC and their trend to transition to the mesenchymal phenotype when they circulate in blood constitute a challenge for their sensitive and specific detection. This review analyzes published studies targeting CTC in patients with RCC, in the context of the biological, pathological, and molecular complexity of this particular cancer. Although further analytical and clinical studies are needed to pinpoint the most suitable approach for highly sensitive CTC detection in RCC patients, it is clear that this field can bring a relevant guide to clinicians and help to RCC patients. Furthermore, as described, a particular subtype of RCC—the ccRCC—can be used as a model to study the relationship between cytomorphological and genetic cellular markers of malignancy, an important issue for the study of CTC from any type of solid cancer.

show abstract

“…Therefore, other methods of CTC detection are being explored for renal cancer . It is interesting to note that despite these detection‐related limitations, the clinical usefulness of CTCs in kidney cancer has been noted, such as the observation of a surge of CTCs after treatment with sunitinib, which is taken as an indication of treatment efficacy …”

Section: Introductionmentioning

confidence: 99%

Current progress in the clinical use of circulating tumor cells as prognostic biomarkers

Jin

Chen

Lan³

et al. 2019

Cancer Cytopathology

View full text Add to dashboard Cite

The process of metastasis is characterized by the shedding of tumor cells into the bloodstream, where they are transported to other parts of the body to seed new tumors. These cells, known as circulating tumor cells (CTCs), have the potential to reveal much about an individual cancer case, and theoretically can aid in the prediction of outcomes and design of precision treatments. Recent advances in technology now allow for the robust and reproducible characterization of CTCs from a simple blood draw. Both the number of circulating cells and important molecular characteristics correlated with clinical phenotypes such as drug resistance can be obtained and used for real‐time prognostic analysis. Molecular characterization can provide a snapshot of the activity of the main tumor (serving as a “liquid biopsy”) and early warnings concerning changes such as the development of resistance, and aid in predicting the efficacy of different therapeutic approaches for treatment optimization. Herein, the authors review the current clinical use of CTCs as prognostic biomarkers for several different cancers. The quantification of CTCs can lead to more accurate staging and decision making regarding options such as adjuvant chemotherapy.

show abstract

The Surge in the Number of Circulating Tumor Cells Following Treatment with Sunitinib for Metastatic Renal Cell Carcinoma

Cited by 6 publications

References 18 publications

Clinical significance of circulating tumour cells and Ki-67 in renal cell carcinoma

Clinical significance of circulating tumour cells and Ki-67 in renal cell carcinoma

Circulating Tumor Cells for the Management of Renal Cell Carcinoma

Current progress in the clinical use of circulating tumor cells as prognostic biomarkers

Contact Info

Product

Resources

About